Viatris Inc. Stock
Viatris Inc. Stock
Pros and Cons of Viatris Inc. in the next few years
Pros
Cons
Performance of Viatris Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Viatris Inc. | 0.240% | -3.108% | -3.412% | 16.159% | 7.106% | -6.641% | -56.113% |
Indivior plc | -1.090% | -6.218% | -5.236% | 8.774% | 30.970% | 133.097% | 670.213% |
Hikma Pharmaceuticals | -0.960% | -3.738% | -4.630% | 0.980% | 0.980% | -24.818% | 5.641% |
Catalent Inc. | -0.250% | -1.188% | 1.767% | 36.662% | 27.209% | -43.341% | 52.621% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first evaluation of Viatris (VTRS) - a pharmaceutical company, the financials reveal a fascinating yet complex picture. While the organization has faced challenges in the past, it seems to have maintained a solid foundation with a mix of ups and downs that demand further exploration.
Stable Total Assets: VTRS boasts a significant total asset base, amounting to $50.02 billion in 2022. Although there has been a slight decline in total assets from $61.55 billion in 2020, it remains a positive aspect for the company.
Reduction in Total Liabilities: The company has managed to reduce its total liabilities from $38.59 billion in 2020 to $28.94 billion in 2022. This decrease in liabilities indicates improved financial health and a reduced debt burden for the company.
Comments
News
Is Viatris a Great Dividend Stock or Just a Value Trap?
Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent